ProShares Ultra Nasdaq Biotechnology (BIB) Price, Holdings, & News

ETF Overview

ProShares Ultra Nasdaq Biotechnology (the Fund) seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day's returns compounded over the period, which will very likely differ from the inverse of the return of the Dow Jones United States Basic Materials Index (the Index) for that period. The Fund does not seek to achieve its stated investment objective over a period of time greater than one day. The Fund invests in derivatives that have similar daily performance characteristics as the inverse of the daily return of the Index. The Fund invests in financial instruments whose value is derived from the value of an underlying asset, interest rate or index. ProShare Advisors LLC is the investment advisor of the Fund.

Key Stats

• Today's Range: $56.86 to $58.01
• 50-Day Range: $49.02 to $58.33
• 52-Week Range: $47.19 to $69.56
• Volume: 12,080 shs
• Average Volume: 10,555 shs
• Market Capitalization: $67.09 million
• Assets Under Management: $63.33 million
• Dividend Yield: 1.49%
• Net Expense Ratio: 0.95%
• Aggregate Rating: Moderate Buy

BIB ETF - Frequently Asked Questions

How have BIB shares performed this year?

ProShares Ultra Nasdaq Biotechnology's stock was trading at $50.66 at the start of the year. Since then, BIB stock has increased by 12.2% and is now trading at $56.86.
View the best growth stocks for 2025 here.

Who are ProShares Ultra Nasdaq Biotechnology's major shareholders?

ProShares Ultra Nasdaq Biotechnology's top institutional shareholders include Capital Investment Advisors LLC (0.83%), Toth Financial Advisory Corp (0.72%), Westwood Wealth Management (0.68%) and Tower Research Capital LLC TRC (0.45%).

How do I buy shares of ProShares Ultra Nasdaq Biotechnology?

Shares of BIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProShares Ultra Nasdaq Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProShares Ultra Nasdaq Biotechnology investors own include Westmoreland Coal (WLB), NVIDIA (NVDA), Alibaba Group (BABA), Advanced Micro Devices (AMD), Meta Platforms (META), Salesforce (CRM).

Fund Details

• Issuer: ProShares
• Fund Name: ProShares Ultra Nasdaq Biotechnology
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:BIB
• Inception Date: 4/6/2010
• Fund Manager: Michael Neches, Tarak Dave
• Web: www.proshares.com
• Phone: +1-240-4976400

Fund Focus

• Asset Class: Equity
• Benchmark: Nasdaq Biotech Index
• Category: Sector
• Focus: Health Care
• Development Level: Developed Markets
• Region: North America
• Number of Holdings: 315

Fund Statistics

• Assets Under Management: $63.33 million
• Average Daily Volume: $12,302.70
• Discount/Premium: -0.10%
• Leveraged: 2.00

Administrator, Advisor and Custodian

• Administrator: J.P. Morgan Investor Services Co.
• Advisor: ProShare Advisors LLC
• Custodian: JPMorgan Chase Bank, N.A.
• Distributor: SEI Investments Distribution Co.
• Transfer Agent: JPMorgan Chase Bank, N.A.
• Trustee: N/A
• Lead Market Maker: Virtu Financial

Options

• Optionable: Optionable
• Options Volume: 4
• Put Options: 6
• Call Options: 4
• Short Interest: 4,400 shs

Miscellaneous

• Outstanding Shares: 1,180,000
• Beta: 1.63
• Creation Unit: 50,000
• Creation Fee: $250.00